Mylod%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

# Mylot%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at (Mylotarg) ## Overview Gemtuzumab ozogamicin is a CD33-directed antibody and DNA intercalator. It targets CD33-expressing cells, primarily malignant cells in acute myeloid leukemia (AML). ## Primary Indications * Treatment of adult patients with newly diagnosed CD33-positive acute myeloid leukemia (AML). * Treatment of adult patients with relapsed or refractory CD33-positive AML. ## Adult Dosing The dosing regimen can vary based on whether it is for newly diagnosed or relapsed/refractory AML. Specific cycles and doses are often determined by institutional protocols and clinical trial data. For **newly diagnosed CD33-positive AML**, a common regimen involves: * **Cycle 1:** 6 mg/m² on Day 1. If tolerated, 3 mg/m² on Day 4 and Day 7. * **Cycle 2:** 3 mg/m² on Day 1, Day 4, and Day 7. For **relapsed or refractory CD33-positive AML**, a common regimen involves: * **First course:** 6 mg/m² on Day 1. If tolerated, 3 mg/m² on Day 4. * **Second course (if tolerated and response is insufficient):** 3 mg/m² on Day 1, Day 4, and Day 7. ## Pediatric Dosing There is **limited established pediatric dosing**. Safety and efficacy in pediatric patients have not been fully determined. Consult specialized pediatric oncology resources or clinical trials for guidance. ## Dose Adjustments Dose adjustments are critical and depend on patient tolerance and the occurrence of adverse events, particularly: * **Hepatotoxicity:** Dose interruptions or discontinuations are common for elevated bilirubin, AST, or ALT. Specific thresholds for dose modification are detailed in the full prescribing information. * **Hematologic Toxicity:** Dose interruptions may be necessary for persistent Grade 3 or 4 neutropenia, thrombocytopenia, or anemia, especially if not related to disease progression. * **Other Adverse Events:** Dose modifications are guided by the severity and persistence of other toxicities. ## Contraindications * Known hypersensitivity to gemtuzumab ozogamicin or any component of the formulation. ## Adverse Effects Common adverse effects include: * **Hepatotoxicity:** Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious and potentially fatal adverse effect. Elevated liver enzymes (ALT, AST, bilirubin) are also common. * **Hematologic:** Neutropenia, thrombocytopenia, anemia, febrile neutropenia. * **Gastrointestinal:** Nausea, vomiting, diarrhea, mucositis. * **Infections:** Sepsis, pneumonia. * **Infusion Reactions:** Fever, chills, rash, dyspnea. * **Bleeding events.** ## Key Drug Interactions * **Hepatotoxic Agents:** Concurrent use with other agents known to cause liver injury may increase the risk of severe hepatotoxicity, including VOD/SOS. * **Myelosuppressive Chemotherapy:** Concurrent use increases the risk of severe myelosuppression. ## Monitoring * **Liver Function Tests (LFTs):** Frequent monitoring of ALT, AST, and bilirubin is essential, especially before and during treatment, and after dose reductions or interruptions. * **Complete Blood Counts (CBCs):** Monitor for neutropenia, thrombocytopenia, and anemia. * **Signs and Symptoms of VOD/SOS:** Monitor for weight gain, ascites, hepatomegaly, jaundice, and abdominal pain. * **Signs of Bleeding:** Monitor for bruising, petechiae, hematuria, or melena. * **Infusion-related reactions:** Monitor vital signs during and after infusion. ## Clinical Pearls * VOD/SOS is a serious risk. Patients with pre-existing liver disease, prior stem cell transplant, or receiving high-dose chemotherapy are at increased risk. * Mylotarg is often administered with other chemotherapeutic agents; therefore, the overall toxicity profile will be influenced by the entire regimen. * Prophylaxis for tumor lysis syndrome and febrile neutropenia should be considered per institutional guidelines. * Infusion reactions can occur, so slow infusion rates and monitoring are important. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for complete details and to verify dosing and safety recommendations.*